Melbourne, Australia – Australia-based Agilex Biolabs, the Asia-Pacific region’s leading bioanalytical laboratory for global clients conducting preclinical and clinical trials, announced at AusBiotech 2019 today it has been selected as a Top 10 Bioanalytical Services Provider by PharmaTech Outlook Magazine (Booth #523).
PharmaTech Outlook Magazine said:
“As the clinical trials sector heads towards a $60 billion market in the next 5 years, quality bioanalytical services that deliver progress and results analysis for a drug therapy are in high demand.
Sponsors and CROs rely on a handful of world-class labs that offer bespoke analysis for study results. Agilex Biolabs, a state-of-the-art lab based in Adelaide, South Australia is one such facility that is making a name for itself as a leader in analysis for studies in Asia, Australia, New Zealand, EU and the USA.
What distinguishes Agilex from competitors is its nimble and flexible team that is capable of meeting tight deadlines.”
Agilex Biolabs, the only FDA-inspected labs in Australia, offers bioanalysis for small molecules and biologics for PK, immunogenicity and biomarkers utilising the two platforms of LC-MS/MS (7) and Immunoassay (MesoScale, Gyrolab).
CEO Jason Valentine said:
“Our FDA-inspected facilities have more than 40 dedicated laboratory staff, and annually support more than 80 clinical trials. This year we will analyse more than 60,000 samples for pharma/biotechs from US, Europe and APAC.”
“By combining specialised expertise, technological innovation and a 20-year track record, we have supported hundreds of preclinical and clinical trials around the world.”
He said compliance is key to the Agilex Biolabs’ success.
“Our world-class bioanalytical facilities have OECD GLP Recognition with NATA (Australian Government OECD GLP Compliance monitoring authority) and ISO 17025 Accreditation for global recognition.”
